Open AccessWomen are predisposed to early dose‐limiting toxicities during adjuvant CAPOX for colorectal cancer
Author(s) -
Nozawa Hiroaki,
Kawai Kazushige,
Sasaki Kazuhito,
Murono Koji,
Emoto Shigenobu,
Yokoyama Yuichiro,
Abe Shinya,
Kishikawa Junko,
Nagai Yuzo,
Sonoda Hirofumi,
Anzai Hiroyuki,
Ozawa Tsuyoshi,
Ishihara Soichiro
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14863
Subject(s) - medicine , colorectal cancer , oxaliplatin , odds ratio , proportional hazards model , logistic regression , oncology , cancer , surgery
Aim Oxaliplatin‐based adjuvant chemotherapy was demonstrated to be beneficial for stage III or high‐risk stage II colorectal cancer (CRC). Moreover, a recent international collaborative trial suggested 3‐months CAPOX as an alternative regimen for low‐risk stage III colorectal cancer (CRC) patients. Thus, it is important to clarify the frequency and predictive markers of dose‐limiting toxicities (DLTs) developed within the short‐course CAPOX cycles. Methods We investigated CRC patients who underwent radical surgery and adjuvant CAPOX therapy at our hospital between December 2010 and February 2021. Patients who received initially reduced doses of CAPOX and those who had early recurrence were excluded. We reviewed the age, sex, comorbidities, physical, laboratory and oncological data and other perioperative factors. The associations between these variables and early DLTs within four cycles of CAPOX were examined by multivariate analyses using logistic regression models. Results Among 168 patients (96 men, mean age: 58.3 years), 120 (71%) developed early DLTs. Patients with early DLTs were predominantly women and sarcopenic and habitual alcohol consumers. On multivariate analyses, only the female sex was an independent predictive factor for early DLTs (odds ratio: 2.61, P = .027). Conclusion Women were prone to early DLTs during adjuvant CAPOX in the current study. Doctors should be aware of the sex difference in the incidence of early DLTs, adjust the CAPOX dosage and provide supportive care for female CRC patients.